Advancing CYP2D6 Pharmacogenetics through a Pharmacoequity Lens

Abstract

Over 20% of US Food and Drug Administration (FDA)‐approved drugs in the United States are metabolized by the hepatic enzyme cytochrome P450 2D6 (CYP2D6). The gene encoding CYP2D6 is highly polymorphic and genetic variation has been shown to impact drug response for many commonly dispensed drugs including opioids and antidepressants. Thus, it is important to understand an individual's CYP2D6 metabolizer status to optimize treatment outcomes for patients taking medications that are metabolized by this enzyme. Consequently, clinical CYP2D6 pharmacogenetic testing is being implemented by a growing number of health centers. Furthermore, clinical guidelines currently recommend adapting therapeutic regimens based on CYP2D6 genotype‐informed phenotype. However, CYP2D6 genetic variation varies considerably across global populations and many allelic variants, or star alleles, are predominantly found in certain ancestral populations. Although CYP2D6 genetic variation has been extensively studied, there is still a paucity of information for many non‐European populations. As has been shown for other pharmacogenes in randomized controlled trials, results from European populations cannot simply be extrapolated to other groups and, in some cases, even has the potential to cause harm. Therefore, enhanced inclusion in pharmacogenetic studies is urgently needed to increase ancestral representation, determine the extent of global CYP2D6 genetic variation (e.g., ancestry‐specific variants), and determine the clinical impact of this variation on clinical treatment outcome. This review highlights knowledge gaps, challenges, and future directions in CYP2D6 pharmacogenomics through a unique pharmacoequity lens to address health inequities that hamper our ability to optimize drug therapy for improved pharmacological outcomes in diverse populations globally.

SLCO1B1functional variants and statin-induced myopathy in people with recent genealogical ancestors from Africa: a population-based real-world study

“…In particular, taking results from Eurocentric study populations and applying them to non-Eurocentric groups (without considering that average results vary between stratified groups) has the potential to cause harm(15). Conducting analyses in genetically diverse study populations and considering all the factors that impact disparities are proposed solutions to prevent further exacerbation(16).…”

CYP2D6 and CYP2C19 Variant Coverage of Commercial Antidepressant Pharmacogenomic Testing Panels Available in Victoria, Australia

“…There are significant differences in CYP2D6 and CYP2C19 variants between biogeographical populations; however, there has been limited investigation of allelic variation in non-European populations [24]. Most PGx knowledge is derived from European and East Asian male populations, with the risk that "understudied populations with more diverse haplotype frequencies are therefore more likely to be affected by imprecision when applying pharmacogenomic annotations to dosage administration" [25].…”

An Introductory Tutorial on Cardiovascular Pharmacogenetics for Healthcare Providers

“…For example, people with predominant East Asian and Oceanian ancestry have the lowest global prevalence of CYP2D6 poor metabolizers, whereas people with predominant European ancestry have the highest global proportion. 83 Patients who are CYP2D6 poor metabolizers have higher systemic concentrations of those 4 beta-blockers, and thus those patients may require lower doses (or more careful dose titration) with those 4 beta-blockers. The FDA Table of Pharmacogenomic Biomarkers in Drug Labeling and the FDA Table of Pharmacogenetic Associations both already include pharmacogenetic information for those 4 beta-blockers and CYP2D6 .…”